[go: up one dir, main page]

FI20051072L - Polyamide oligonucleotide derivatives, their preparation and their use - Google Patents

Polyamide oligonucleotide derivatives, their preparation and their use Download PDF

Info

Publication number
FI20051072L
FI20051072L FI20051072A FI20051072A FI20051072L FI 20051072 L FI20051072 L FI 20051072L FI 20051072 A FI20051072 A FI 20051072A FI 20051072 A FI20051072 A FI 20051072A FI 20051072 L FI20051072 L FI 20051072L
Authority
FI
Finland
Prior art keywords
preparation
oligonucleotide derivatives
polyamide oligonucleotide
polyamide
derivatives
Prior art date
Application number
FI20051072A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI117939B (en
Inventor
Eugen Uhlmann
Gerhard Breipohl
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of FI20051072L publication Critical patent/FI20051072L/en
Application granted granted Critical
Publication of FI117939B publication Critical patent/FI117939B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polyamides (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI20051072A 1994-03-14 2005-10-24 Polyamide oligonucleotide derivatives, their preparation and use FI117939B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4408528A DE4408528A1 (en) 1994-03-14 1994-03-14 Peptide oligonucleotide derivatives, their preparation and use
DE4408528 1994-03-14

Publications (2)

Publication Number Publication Date
FI20051072L true FI20051072L (en) 2005-10-24
FI117939B FI117939B (en) 2007-04-30

Family

ID=6512694

Family Applications (2)

Application Number Title Priority Date Filing Date
FI951132A FI117135B (en) 1994-03-14 1995-03-10 Polyamide oligonucleotide derivatives, their preparation and use
FI20051072A FI117939B (en) 1994-03-14 2005-10-24 Polyamide oligonucleotide derivatives, their preparation and use

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FI951132A FI117135B (en) 1994-03-14 1995-03-10 Polyamide oligonucleotide derivatives, their preparation and use

Country Status (13)

Country Link
EP (2) EP1113021B1 (en)
JP (1) JP4620810B2 (en)
KR (1) KR100416864B1 (en)
CN (1) CN100379756C (en)
AT (2) ATE220070T1 (en)
AU (1) AU698210B2 (en)
CA (1) CA2144475C (en)
DE (3) DE4408528A1 (en)
DK (2) DK1113021T3 (en)
ES (2) ES2179080T3 (en)
FI (2) FI117135B (en)
NO (1) NO314664B1 (en)
PT (2) PT1113021E (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710164B1 (en) 1993-11-22 2004-03-23 Peter E. Nielsen Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
DE4438918A1 (en) 1994-11-04 1996-05-09 Hoechst Ag Modified oligonucleotides, their preparation and their use
US6150510A (en) 1995-11-06 2000-11-21 Aventis Pharma Deutschland Gmbh Modified oligonucleotides, their preparation and their use
DE19502912A1 (en) 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilized Oligonucleotides
PT739898E (en) * 1995-03-13 2002-03-28 Aventis Pharma Gmbh PHOSPHONUCLETIC ACID MONO-ESTERS PROCESS FOR PREPARING AND USING
DE19532553A1 (en) * 1995-09-04 1997-03-06 Hoechst Ag Process for the preparation of substituted N-ethyl-glycine derivatives
GB2324534B (en) * 1996-01-06 2000-05-10 Danbiosyst Uk Composition for delivery of nucleic acid to a cell
ATE267247T1 (en) * 1996-05-24 2004-06-15 Aventis Pharma Gmbh REAGENT AND METHOD FOR INHIBITING N-RAS EXPRESSION
US6191165B1 (en) * 1996-05-31 2001-02-20 Allelix Neuroscience Inc. Pharmaceutical for treatment of neurological and neuropsychiatric disorders
EP1014966B1 (en) * 1996-05-31 2006-08-02 Allelix Neuroscience Inc. Pharmaceutical for treatment of neurological and neuropsychiatric disorders
CA2261566A1 (en) * 1996-07-24 1998-01-29 Buchardt, Dorte Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
DE19637339A1 (en) * 1996-09-13 1998-03-19 Hoechst Ag Methods for amplifying nucleic acids
CA2303299C (en) 1997-09-12 2016-02-23 Exiqon A/S Oligonucleotide analogues
WO1999034014A2 (en) * 1997-12-23 1999-07-08 Roche Diagnostics Gmbh A method for the determination of a nucleic acid
US5952202A (en) * 1998-03-26 1999-09-14 The Perkin Elmer Corporation Methods using exogenous, internal controls and analogue blocks during nucleic acid amplification
DE19935303A1 (en) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonucleotides to inhibit the expression of human eg5
US6316230B1 (en) 1999-08-13 2001-11-13 Applera Corporation Polymerase extension at 3′ terminus of PNA-DNA chimera
US7205105B2 (en) 1999-12-08 2007-04-17 Epoch Biosciences, Inc. Real-time linear detection probes: sensitive 5′-minor groove binder-containing probes for PCR analysis
DE10019135A1 (en) 2000-04-18 2001-10-31 Aventis Pharma Gmbh Polyamide nucleic acid derivatives, agents and processes for their preparation
US7348146B2 (en) 2003-10-02 2008-03-25 Epoch Biosciences, Inc. Single nucleotide polymorphism analysis of highly polymorphic target sequences
CA2542768A1 (en) 2003-10-28 2005-05-12 Epoch Biosciences, Inc. Fluorescent probes for dna detection by hybridization with improved sensitivity and low background
DE102006034319A1 (en) * 2006-07-21 2008-01-31 Ugichem Gmbh Chiral phosphonic ester or phosphonic acid substituted compounds
EP2781523A1 (en) 2013-03-18 2014-09-24 Miltenyi Biotec GmbH Lipophilic oligonucleotide analogs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0972779A3 (en) * 1987-10-28 2004-10-20 Howard Florey Institute Of Experimental Physiology And Medicine Oligonucleotide-polyamide conjugates
WO1993024511A1 (en) * 1992-05-29 1993-12-09 Howard Florey Institute Of Experimental Physiology And Medicine Oligonucleotide-polyamide conjugates
US5138045A (en) * 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
DK51092D0 (en) * 1991-05-24 1992-04-15 Ole Buchardt OLIGONUCLEOTIDE ANALOGUE DESCRIBED BY PEN, MONOMERIC SYNTHONES AND PROCEDURES FOR PREPARING THEREOF, AND APPLICATIONS THEREOF
US5646261A (en) * 1992-01-22 1997-07-08 Hoechst Aktiengesellschaft 3'-derivatized oligonucleotide analogs with non-nucleotidic groupings, their preparation and use
KR930016437A (en) * 1992-01-22 1993-08-26 귀틀라인, 슈미트 Oligonucleotide Analogues, Methods for Making and Uses thereof

Also Published As

Publication number Publication date
FI951132L (en) 1995-09-15
EP0672677A2 (en) 1995-09-20
JPH07278179A (en) 1995-10-24
PT672677E (en) 2002-11-29
NO314664B1 (en) 2003-04-28
EP0672677A3 (en) 1996-01-17
FI117939B (en) 2007-04-30
FI117135B (en) 2006-06-30
ATE335760T1 (en) 2006-09-15
FI951132A0 (en) 1995-03-10
ATE220070T1 (en) 2002-07-15
CA2144475A1 (en) 1995-09-15
AU1479895A (en) 1995-09-21
NO950955L (en) 1995-09-15
PT1113021E (en) 2006-12-29
AU698210B2 (en) 1998-10-29
EP1113021A3 (en) 2001-07-11
CN100379756C (en) 2008-04-09
EP1113021B1 (en) 2006-08-09
KR100416864B1 (en) 2006-01-27
JP4620810B2 (en) 2011-01-26
DE59511061D1 (en) 2006-09-21
DE59510252D1 (en) 2002-08-08
DK0672677T3 (en) 2002-10-28
DK1113021T3 (en) 2006-12-11
DE4408528A1 (en) 1995-09-28
KR950032265A (en) 1995-12-20
HK1012003A1 (en) 1999-07-23
CA2144475C (en) 2010-06-08
ES2179080T3 (en) 2003-01-16
EP1113021A2 (en) 2001-07-04
NO950955D0 (en) 1995-03-13
ES2269239T3 (en) 2007-04-01
HK1038568A1 (en) 2002-03-22
CN1112126A (en) 1995-11-22
EP0672677B1 (en) 2002-07-03

Similar Documents

Publication Publication Date Title
FI955235L (en) Oxazolidinion derivatives, their preparation and use
FI20051072L (en) Polyamide oligonucleotide derivatives, their preparation and their use
FI962927A7 (en) Tetracycline derivatives, preparation method and use
NL300295I2 (en) 3,3-diarylpropylamines, their use and preparation
FI955913A0 (en) New erythromycin derivatives, methods for their preparation and their use as drugs
FI952359A7 (en) Metallocene catalyst systems, their preparation and use
FI964311L (en) Bifunctional protein, preparation and use
EE200000037A (en) Acylpiperazinylpyrimidines Derivatives, Their Preparation and Use as Medicaments
CY2013003I2 (en) PHOSPHONOCHEMICAL DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND USE THEREOF
EE04721B1 (en) Phenylxanthine derivatives, processes for their preparation and use
EE200200160A (en) 2'-Substituted 1,1'-biphenyl-2-carboxamides, their use and pharmaceutical preparations
EE200000621A (en) Anti-picornaviral compounds, their preparation and use
FI972629A7 (en) Aryl and heteroarylsulfonamide derivatives, their preparation and their use as endothelin antagonists
FI951817A7 (en) Organoaluminate product, its preparation and use
EE9600172A (en) Purin-6-one derivatives, their preparation method, use in the preparation of medicaments and medicaments
FI950458A7 (en) N-(3-aminopropyl)-N-phenyl-5,6,7,8-tetrahydronaphthalene-2-carboxamide derivatives, their preparation and therapeutic use
FI970997L (en) Benzocycloalkene compounds, their preparation and use
FI940425A7 (en) Modified oligodeoxyribonucleotides, their preparation and their therapeutic use
FI954946A7 (en) Quinoxalines, process for their preparation and use
EE200000207A (en) 8-Azabicyclo [3.2.1] octane-3-methanamine derivatives, their preparation and therapeutic use
FI970750L (en) Indole-2,3-dione-3-oxime derivatives, their preparation and use
EE200000018A (en) 6-Pyrrolidin-2-ylpyridines, their Preparation and Therapeutic Use
FI954141L (en) Oxazoloquinolone derivatives, their preparation and their use in therapy
FI965172A7 (en) New amido-quinoxalinediones, their preparation and use
EE03441B1 (en) 5-Naphthalen-1-yl-1,3-dioxane derivatives, their preparation and therapeutic use

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 117939

Country of ref document: FI

MM Patent lapsed